Tuesday, September 24, 2024 10:27:18 PM
The company doesn't intend to make money. That's what these paid pumper posters are here for....to keep retail from realizing what a POS company this is. Let's just slow roll the smallest market with notorious reiumbursement while building up LP's advent. Who cares about commercialization and actually self sustaining your company with actual revenue when you can just dilute the piss out of retail and help fund the CEO's CDMO. Why didn't they ever reveal their post trial meeting notes with the FDA? Maybe that's why they choose UK....not this BS excuse about scale up. They got no money to fund scale up. So that argument is crap. You do the manual method so you can help fund scale up. You don't do stupid big bang approach to automation. Anyone that has ever done automation knows this....but keep trying to trick retail with this MFG MFG MFG BS carrot.
Let's blame manipulation for this raping of actual shareholders. The paid pumpers are helping justify this nonsense like this is normal behavior for all pre-rev bios....gas lighting at it's absolute finest. I can't believe people are claiming this is revolutionary....We have CAR-T, TIL, and we have engineered t-cell therapy all on the market now. But yeah NWBO is trailblazing how to slow roll the application process and never commercializing.....that's what they do.
Let's blame manipulation for this raping of actual shareholders. The paid pumpers are helping justify this nonsense like this is normal behavior for all pre-rev bios....gas lighting at it's absolute finest. I can't believe people are claiming this is revolutionary....We have CAR-T, TIL, and we have engineered t-cell therapy all on the market now. But yeah NWBO is trailblazing how to slow roll the application process and never commercializing.....that's what they do.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
